Exact Mass: 419.0218

Exact Mass Matches: 419.0218

Found 11 metabolites which its exact mass value is equals to given mass value 419.0218, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Luzonensol acetate

Luzonensol acetate

C17H25Br2O2 (419.0221)


   
   

2-[(3-iodo-6-nitroindazol-1-yl)methoxy]ethyl-trimethylsilane

2-[(3-iodo-6-nitroindazol-1-yl)methoxy]ethyl-trimethylsilane

C13H18IN3O3Si (419.0162)


   

(+)-Clopidogrel bisulfate

(+)-Clopidogrel bisulfate

C16H18ClNO6S2 (419.0264)


   

Ethyl 6-bromo-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

Ethyl 6-bromo-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate

C19H18BrNO3S (419.0191)


   

Clopidogrel bisulfate

Clopidogrel bisulfate

C16H18ClNO6S2 (419.0264)


C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively[1]. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation[2].Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[5].

   

iron(3+),tribenzoate

iron(3+),tribenzoate

C21H15FeO6 (419.0218)


   

Plavix

Plavix

C16H18ClNO6S2 (419.0264)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors

   

(Rac)-PT2399

(Rac)-PT2399

C17H10F5NO4S (419.0251)


(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM[1].

   

Kobe2602

Kobe2602

C14H9F4N5O4S (419.0311)


Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity[1].

   

PT2399

PT2399

C17H10F5NO4S (419.0251)


PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo[1][2][3].